BCD-248

Phase 3Small molecule

BBiocad

BCD-248 is one of 40 small molecule programs targeting Myeloma Multiple. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloma MultipleRecruiting

Multiple MyelomaRecruiting

Myeloma MultiplePhase 3

Recruiting

Multiple MyelomaPhase 2

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

17 2

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 3

Opdivo

Bristol-Myers Squibb

Phase 3

11 4

Treanda

AAzurity Pharmaceuticals

Phase 3

19 5

Neulasta

Amgen

Phase 3

5 6

Cytosar

Teva

Phase 3

4 7

Busulfex

Akero Therapeutics

Phase 3

15 8

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 10

Mezigdomide

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Multiple Myeloma

NCT06668792

Q4 2032

Phase 3Recruiting

Myeloma Multiple

NCT07742215

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·BBiocad·Phase 2·NCT06668792·100 enrolled

Myeloma Multiple1 trial

A Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·BBiocad·Phase 3·NCT07742215·390 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BCD-248. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCD-248 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCD-248. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiocad

BCD-248

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2032

Trials by Indication[1]

Multiple Myeloma1 trial

Myeloma Multiple1 trial

References

Drug Info

Quick Facts

Related News